Penumbra reported strong third-quarter 2025 results, with revenue rising 17.8% year-over-year to US$354.7 million and earnings surpassing estimates, prompting management to raise full-year revenue guidance.

In the days following the results, pre-arranged insider sales by two senior executives coincided with broad analyst optimism about momentum in the thrombectomy and embolization segments, underscoring confidence in the company's product innovation.

We'll examine how Penumbra's upward revenue guidance revision signals a potential shift in the company's long-term growth outlook.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 35 best rare earth metal stocks of the very few that mine this essential strategic resource.

To be a Penumbra shareholder, you need to believe in the company’s continued leadership in minimally invasive vascular therapies and its ability to stay ahead in innovation amid rising competition. The recent strong quarterly results, combined with pre-scheduled executive share sales, appear to have no material impact on the biggest short-term catalyst: clinical adoption driven by new data in thrombectomy and embolization, while margin pressure from aggressive industry pricing remains the most immediate risk.

The release of positive STORM-PE trial results stands out as a key announcement closely tied to current catalysts, as robust clinical data favoring Penumbra’s technology may accelerate procedural uptake and drive segment growth. In an environment where guideline adoption can reshape competitive positioning, supportive evidence like this can hold particular relevance for near-term performance drivers and investors’ focus.

In contrast, investors should remain conscious of how market pricing pressures and product commoditization could challenge Penumbra’s...

Read the full narrative on Penumbra (it's free!)

Penumbra's outlook forecasts $1.9 billion in revenue and $274.7 million in earnings by 2028. This scenario assumes annual revenue growth of 13.6% and an earnings increase of $127 million from the current $147.7 million.

Uncover how Penumbra's forecasts yield a $306.79 fair value, a 4% upside to its current price.

Estimates from four members of the Simply Wall St Community place Penumbra’s fair value between US$107.91 and US$306.79 per share. While clinical data has fueled optimism about accelerating adoption, views differ widely and you are encouraged to consider multiple perspectives before evaluating Penumbra’s prospects for sustainable growth.

Explore 4 other fair value estimates on Penumbra - why the stock might be worth less than half the current price!

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Penumbra research is our analysis highlighting 2 key rewards that could impact your investment decision.

Our free Penumbra research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Penumbra's overall financial health at a glance.

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Find companies with promising cash flow potential yet trading below their fair value.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include PEN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com